Agosti Marcello Pignagnoli net worth and biography

Agosti Pignagnoli Biography and Net Worth

Insider of Takeda Pharmaceutical

Marcello Agosti is the interim head of strategy and portfolio development for Takeda and is responsible for Takeda’s business development activities, including M&A and Corporate Development.

Marcello led the Shire acquisition and several other strategic acquisitions for Takeda, including ARIAD Pharmaceuticals and TiGenix as well asset acquisitions such as TAK-279 from Nimbus Therapeutics and fruquintinib from HUTCHMED. He also spearheaded a number of strategic divestments of non-core assets as part of Takeda’s commitment after the Shire acquisition. Marcello and his group continue to be active on inbound transactions in Takeda’s core therapy areas.

Prior to joining Takeda, Marcello worked in business development at Novartis in the U.K. and Switzerland. Before joining the pharmaceutical industry, he was a consultant at McKinsey & Company.

He holds an MBA from the University of Oxford and a business administration degree from Bocconi University, Milan.

Marcello is based in Boston.

What is Agosti Marcello Pignagnoli's net worth?: The estimated net worth of Agosti Marcello Pignagnoli is at least $3.09 million as of August 10th, 2026. Pignagnoli owns 176,977 shares of Takeda Pharmaceutical stock worth more than $3,089,134 as of August 13th. This net worth approximation does not reflect any other assets that Pignagnoli may own. Learn More about Agosti Marcello Pignagnoli's net worth.
How do I contact Agosti Marcello Pignagnoli?: The corporate mailing address for Pignagnoli and other Takeda Pharmaceutical executives is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. Takeda Pharmaceutical can also be reached via phone at (166) 204-2111 and via email at [email protected]. Learn More on Agosti Marcello Pignagnoli's contact information.
Has Agosti Marcello Pignagnoli been buying or selling shares of Takeda Pharmaceutical?: During the last ninety days, Agosti Marcello Pignagnoli has sold $392,564.70 in shares of Takeda Pharmaceutical stock. Most recently, Agosti Marcello Pignagnoli sold 22,957 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a transaction totalling $392,564.70. Following the completion of the sale, the insider now directly owns 176,977 shares of the company's stock, valued at $3,026,306.70. Learn More on Agosti Marcello Pignagnoli's trading history.
Who are Takeda Pharmaceutical's active insiders?: Takeda Pharmaceutical's insider roster includes Lauren Duprey (Chief Transformation Officer), Samaan Farajallah (Insider), Anne Furney (General Counsel), Julie Kim (Representative Director – President and CEO), Agosti Pignagnoli (Insider), Giles Platford (President, International Business Unit), Gabriele Ricci (Insider), and Elaine Shannon (President, Global Supply & Quality). Learn More on Takeda Pharmaceutical's active insiders.
Are insiders buying or selling shares of Takeda Pharmaceutical?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 444,100 shares worth more than $7,594,110.00. The most recent insider tranaction occured on August, 10th when insider Ramy Riad Ahmed Ibrahim sold 7,277 shares worth more than $124,436.70. Insiders at Takeda Pharmaceutical own 0.0% of the company. Learn More about insider trades at Takeda Pharmaceutical.
Information on this page was last updated on 8/10/2026.

Agosti Marcello Pignagnoli Insider Trading History at Takeda Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2026	Sell	22,957	$17.10	$392,564.70	176,977

Agosti Marcello Pignagnoli Buying and Selling Activity at Takeda Pharmaceutical

Takeda Pharmaceutical Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Today's Range

Now: $17.42

$17.38

$17.47

50 Day Range

MA: $16.49

$15.41

$17.78

2 Week Range

Now: $17.42

$12.99

$18.90

Volume

378,150 shs

Average Volume

3,167,810 shs

Market Capitalization

$55.80 billion

P/E Ratio

51.22

Dividend Yield

2.75%

Beta

N/A